J
John R. Graybill
Researcher at University of Texas Health Science Center at San Antonio
Publications - 183
Citations - 10577
John R. Graybill is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Amphotericin B & Itraconazole. The author has an hindex of 53, co-authored 183 publications receiving 10225 citations. Previous affiliations of John R. Graybill include University of Texas at San Antonio & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.
Thomas F. Patterson,William R. Kirkpatrick,Mary H. White,John W. Hiemenz,John R. Wingard,Bertrand Dupont,Michael G. Rinaldi,David A. Stevens,John R. Graybill +8 more
TL;DR: It is confirmed that mortality from invasive aspergillosis in severely immunosuppressed patients remains high even with standard amphotericin B, and new approaches and new therapies are needed to improve the outcome.
Journal ArticleDOI
NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
David W. Denning,David W. Denning,Jeanette Y. Lee,Jeanette Y. Lee,John S. Hostetler,John S. Hostetler,Peter G. Pappas,Peter G. Pappas,Carol A. Kauffman,Carol A. Kauffman,Daniel H. Dewsnup,Daniel H. Dewsnup,John N. Galgiani,John N. Galgiani,John R. Graybill,John R. Graybill,Alan M. Sugar,Alan M. Sugar,Antonino Catanzaro,Antonino Catanzaro,Harry A. Gallis,Harry A. Gallis,John R. Perfect,John R. Perfect,Bonita Dockery,Bonita Dockery,William E. Dismukes,William E. Dismukes,David A. Stevens,David A. Stevens +29 more
TL;DR: Oral itraconazole is a useful alternative therapy for invasive aspergillosis with response rates apparently comparable to amphotericin B, and relapse rates among those who completed therapy and those who discontinued early for possible toxicity were 12% and 40%, respectively.
Journal ArticleDOI
Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis
John R. Graybill,Jack D. Sobel,Michael S. Saag,C. Van Der Horst,William G. Powderly,Gretchen A. Cloud,Laura Riser,Richard J. Hamill,William E. Dismukes +8 more
TL;DR: After receiving antifungal therapy, those patients whose CSF pressure was reduced by >10mm or did not change had more frequent clinical response at 2 weeks than did those whose pressure increased >10 mm (P /=250 mm H2O be treated with large-volume CSF drainage).
Journal ArticleDOI
Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria
Brahm H. Segal,Raoul Herbrecht,David A. Stevens,David A. Stevens,Luis Ostrosky-Zeichner,Jack D. Sobel,Claudio Viscoli,Thomas J. Walsh,Johan Maertens,Thomas F. Patterson,John R. Perfect,Bertrand Dupont,John R. Wingard,Thierry Calandra,Carol A. Kauffman,John R. Graybill,Lindsey R. Baden,Peter G. Pappas,John E. Bennett,Dimitrios P. Kontoyiannis,Catherine Cordonnier,Maria Anna Viviani,Jacques Bille,Nikolaos G. Almyroudis,L. Joseph Wheat,Wolfgang Graninger,Eric J. Bow,Steven M. Holland,Bart Jan Kullberg,William E. Dismukes,Ben E. De Pauw +30 more
TL;DR: An expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes.
Journal ArticleDOI
Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions
Issam I Raad,Ray Y Hachem,Raoul Herbrecht,John R. Graybill,R. S. Hare,Gavin Corcoran,Dimitrios P. Kontoyiannis +6 more
TL;DR: It is suggested that posaconazole is useful for the treatment of invasive fusariosis after a retrospective analysis of patients from 3 open-label clinical trials.